- In April 2023, Pfizer Inc. announced promising Phase 3 clinical trial results for Somatrogon, its long-acting recombinant human growth hormone therapy for pediatric growth hormone deficiency. The therapy demonstrated non-inferiority compared to daily injections, with a favorable safety profile. This milestone strengthens Pfizer’s position in the rHGH market and reinforces its commitment to improving treatment adherence and patient outcomes through innovative delivery solutions.
- In March 2023, Novo Nordisk A/S launched Sogroya® (somapacitan), its once-weekly recombinant human growth hormone therapy, in selected European markets following EMA approval. This marks a significant step in reducing treatment burden for patients, offering a more convenient alternative to daily injections. The rollout supports Novo Nordisk’s strategy to expand its endocrine care portfolio across global markets with next-generation biologics.
- In March 2023, GeneScience Pharmaceuticals Co., Ltd. (GenSci), a China-based biopharmaceutical firm, expanded its domestic distribution network for its rHGH product, Jintropin®, to rural healthcare centers across inland provinces. The initiative aims to increase accessibility for children diagnosed with growth hormone deficiencies in underserved regions, reflecting GenSci’s broader mission to bridge healthcare equity gaps through localized partnerships and affordable biosimilar solutions.
- In February 2023, LG Chem Ltd. initiated a pivotal trial of its novel long-acting growth hormone candidate, LB03002, targeting both pediatric and adult growth hormone deficiency indications. The Korea-based company’s sustained investment in biopharmaceutical R&D highlights its ambition to enter competitive international markets with extended-duration rHGH formulations that reduce injection frequency and enhance patient compliance.
- In January 2023, Biocon Biologics Ltd., a subsidiary of Biocon Limited, announced its plan to commercialize a biosimilar version of recombinant human growth hormone across Latin America through a strategic alliance with Brazil-based Libbs Farmacêutica. This move not only reinforces Biocon’s expansion into emerging markets but also emphasizes the growing demand for cost-effective biologics that meet regional healthcare needs while ensuring regulatory compliance and affordability.
